FindTrial
Sign In

DCC-3014

DRUG3 trials

Sponsors

Deciphera Pharmaceuticals Inc., Memorial Sloan Kettering Cancer Center

Conditions

Advanced SarcomaDedifferentiated LiposarcomaHigh Grade SarcomaLeiomyosarcomaMyxofibrosarcomaPatients with Advanced Tumors and Tenosynovial Giant Cell TumorSarcomaTenosynovial Giant Cell Tumor

Phase 1

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
CompletedNCT04242238
Memorial Sloan Kettering Cancer CenterAdvanced Sarcoma, Dedifferentiated Liposarcoma, High Grade Sarcoma +4
Start: 2020-01-22End: 2025-08-26Updated: 2025-08-28
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Active, not recruitingCTIS2024-514933-39-00
Deciphera Pharmaceuticals Inc.Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Start: 2020-05-26Target: 54Updated: 2025-08-28

Phase 3

A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)
Active, not recruitingCTIS2024-513624-42-00
Deciphera Pharmaceuticals Inc.Tenosynovial Giant Cell Tumor
Start: 2021-12-16Target: 79Updated: 2025-09-23

Related Papers

A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.
Journal of Clinical Oncology2021-05-2011 citations